Gessel has advised Bioceltix on non-prospective public offering, preparation for a debut on the Warsaw Stock Exchange regulated market, and transfer of stock quotes from the alternative trading system NewConnect to the regulated market. SSW Pragmatic Solutions reportedly also advised Bioceltix.
According to Gessel, "the transaction was approved by the Polish Financial Supervision Authority on July 28 this year, and the first day of listing the company's shares on the regulated market was set for September 5, 2022."
Bioceltix is a Wroclaw-headquartered company that develops therapies in veterinary medicine.
The Gessel team included Partner Krzysztof Marczuk, Managing Associate Magdalena Szeplik, Senior Associate Jakub Rowicki, Associate Michal Dunikowski, and Junior Associate Piotr Blank.
